Abstract
Hematopoietic stem cell transplantation (HSCT) with a matched sibling donor is the first-line therapy for pediatric aplastic anemia (AA). Whether to perform an alternative HSCT or use immunosuppressive therapy (IST) including anti-thymocyte globulin (ATG) is still unclear if suitable donor is not available. IST with concomitant eltrombopag, a thrombopoietin receptor agonist, shows a good response in adult.1 However, data of eltrombopag is limited in pediatric with low prevalence AA, showing equivocal result.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
